Announcements

Conference: 60th Annual Scientific Meeting of the European Society for Clinical Investigation (ESCI)
Date: 3–5 June 2026
Location: Lisbon, Portugal

MDPI will participate as an exhibitor at the 60th Annual Scientific Meeting of the European Society for Clinical Investigation. We welcome researchers and professionals to visit our booth and engage with our team.

The 60th Annual Scientific Meeting (ASM) of the European Society for Clinical Investigation (ESCI) will be held from 3 to 5 June 2026. It can bring together 500–600 scientists, medical professionals, and innovation leaders from across Europe and beyond to explore the theme “Research in Action: Building Healthier Futures”. The scientific program will feature a rich blend of disciplines—spanning cardiovascular science, endocrinology, obesity, metabolism and MASLD, mitochondrial biology, oncology and immunology, rheumatology, and neurosciences. This year, we will shine a spotlight on life transitions in women, unravelling health and disease journeys from pregnancy to menopause. The program will also highlight today’s most transformative biomedical breakthroughs, from AI-enabled diagnostics to gene editing and precision therapies.

The following open access journals will be represented:

• Reports;
• Medicina;
• Diagnostics;
• JPM;
• BioMed;
• Complications;
• Pharmacy;
• NeuroSci;
• JCRM;
• Current Oncology;
• JCM;
• Physiologia;
• Proteomes;
• Diseases.

If you are planning to attend the above event, please feel free to start a conversation with us. Our delegates look forward to meeting you in person and answering any questions that you may have. For more information, please visit https://barcelo.eventsair.com/QuickEventWebsitePortal/esci-2026/web.

We are honored to announce that Prof. Dr. William Gerwick will serve as the Chair of the 2026 Tu Youyou Award Committee.

A world-renowned authority in marine natural products chemistry and pharmacology, Professor Gerwick is a Distinguished Professor at both the Scripps Institution of Oceanography and the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California San Diego (UCSD). His pioneering work at the intersection of ocean sciences and drug discovery makes him a fitting leader for an award centered on transformative medicinal breakthroughs.

Under Professor Gerwick’s stewardship, the 2026 Tu Youyou Award Committee will focus on recognizing innovative and impactful research in natural products chemistry and medicinal chemistry, particularly work with the potential to drive meaningful advances in both scientific understanding and human health.

To provide further insight into his perspectives, we include below an interview with Professor Gerwick, in which he reflects on his scientific journey, his views on the field, and his vision for the Tu Youyou Award.

A Conversation with the Chair

1. Could you please introduce yourself and your research journey?

My research focuses on the natural products of marine algae and cyanobacteria, their application in medicine, their biosynthesis using genomic approaches, and innovative methods in the structure elucidation of natural products.

I received my BS degree from the University of California at Davis, my PhD from the University of California at San Diego, and conducted postdoctoral work at the University of Connecticut. After a couple of years in a junior faculty position at the Department of Chemistry at the University of Puerto Rico, I spent 21 years as Professor of Pharmacy at Oregon State University. In 2005, I returned to my PhD institution at the Scripps Institution of Oceanography and the Skaggs School of Pharmacy and Pharmaceutical Sciences at UC San Diego, where I am currently a Distinguished Professor of Oceanography and Pharmaceutical Sciences.

Throughout my career, I have been dedicated to advancing the field through both leadership and mentorship. I have served as president of the American Society of Pharmacognosy, chaired and co-chaired several major research conferences, and served as an associate editor for the Journal of Natural Products. I am a Fellow of the American Association for the Advancement of Science (AAAS) and of the American Society of Pharmacognosy. I have trained over 100 doctoral and postdoctoral students, and my research group has published nearly 500 papers and more than 25 patents on topics in the natural product sciences and medicinal chemistry.

2. What motivated you to accept the role of Chair of the 2026 Tu Youyou Award Committee?

Of course, I am a huge supporter of all awards that are given in recognition of excellent scientific research, and especially so in the natural products sciences and medicinal chemistry. However, this award is truly special in that it recognizes scientific excellence as well as impact, and is given in the name of an individual, Tu Youyou, who clearly had many challenges along the path to reach the pinnacle of her success. Not only was she the first Chinese person to win a Nobel prize in this area, but she was also the first Chinese woman to receive a Nobel prize, and this was achieved without graduate education in China or elsewhere. It’s a true testament to what can be achieved by hard work, determination, and vision. To read the history of her extraordinary approach to discovering novel antimalarial compounds from Traditional Chinese Medicine is truly inspirational. It is, therefore, the inspiration provided by the extraordinary life and career of Tu Youyou that motivated me to accept the Chair of the Award Committee for 2026.

3. How do you view the role of natural products chemistry and medicinal chemistry in today’s scientific landscape, and what major advances over the past decade have shaped this field?

A quite remarkable integration of fields is currently transforming natural products science and medicinal chemistry. In natural products, we are seeing integration of different omics methods, from metabolites to proteins to nucleic acids. Sophisticated biological and pharmacological approaches are driving the discovery of exquisitely potent and selective natural products. Advances are being made to integrate molecular-level recognition of natural products with chemical ecological studies, and sophisticated methods of structure determination using Artificial Intelligence or pioneering new tools such as microED are being applied with increasing frequency. High-level synthetic methodologies, such as protecting group-free synthetic routes, are enhancing medicinal chemistry, accelerating the identification of lead molecules with attractive pharmaceutical properties at an increasing pace.

4. How do you consider the balance between fundamental discovery (e.g., new molecules or mechanisms) and practical impact (e.g., therapeutic applications)?

Many individuals are excellent scientists and mentors, and have essential roles in developing our culture that values science and the scientific method. It should also be pointed out that not all scientific discoveries are going to have a broad societal impact, but they are nevertheless critical to the overall body and structure of science. But it is a truly remarkable individual who makes a key scientific discovery, recognizes its potential value to society in general, and then has the skills and determination to bring it forward as a useful product. That was the type of person the Tu Youyou is, and that is the type of person who is honored by the prize in her name.

5. What do you see as the key challenges or opportunities currently facing the field?

We are on the crux of an amazing revolution in many of the sciences, including natural products and medicinal chemistry; the purposeful application of Artificial Intelligence to solving many of the difficulties involved in the search for new pharmaceuticals from Nature. AI is transforming how we select organisms for study, what pharmaceutical targets to go after, rapidly resolving the chemical structures of new compounds, identifying efficient routes to their chemical synthesis, understanding their molecular mechanisms of action, and finally, designing their clinical application. The role of people in these pursuits is changing. Increasingly, the human role will be providing overall vision: what can we do? What should we do? And it is important to remember that AI is providing hypotheses, not truth. Scientists with expert domain knowledge will be critical for discerning the correctness of hypotheses put forth by AI. Altogether, advances in technology, expanding knowledge, and the appropriate use of AI methods are preparing society to be able to address emerging diseases, such as pandemics, as well as conditions that are not effectively treated by currently existing therapeutics.

6. How do you expect the Tu Youyou Award to contribute to the advancement of natural product chemistry, medicinal chemistry, and human health over the coming years?

The Tu Youyou Award is potentially transformative for the broad fields of natural products science and medicinal chemistry as it brings a significantly increased level of visibility to these topics and their contributions to human health. It will be crucial to have excellent communication to news agencies, social media and other communication outlets so that the general public is informed and educated on the high impact of these natural product/medicinal chemistry contributions. This will bring increased funding, attract promising students, and generally enrich the interface of these fields with the health sector.

7. What message would you like to convey to the research community and the public during this open nomination phase?

This prize gives broad societal visibility to the role that natural products have had in shaping a majority of our current medicines, as well as understanding the life forms with whom we share the planet. Further, it recognizes a woman scientist working under sub-optimal conditions who could persevere and make discoveries of global impact. The prize and what it represents, therefore, inspires current and future generations to engage in the study of Nature and its relationship to Human Health, to overcome adversity, and to aspire to making one’s life impactful.

About the Tu Youyou Award

Established in 2016, the Tu Youyou Award seeks to honor those who excel in the fields of natural products chemistry and medicinal chemistry. This award offers a total prize of CHF 100,000, which will be equally divided among the winners if there is more than one, with each recipient receiving an award medal and a certificate.

The 2026 Tu Youyou Award is open for nominations until 31 October 2026. We encourage all eligible candidates to participate in this prestigious recognition, as this award not only honors individual achievement but also encourages further scientific exchange, exploration and discovery in critical areas of medicine.

If you are interested in participating, please visit the Tu Youyou Award website for more information on the nomination requirements.

Conference: The 2026 Annual Congress of the European Association for Cancer Research
Date: 8–11 June 2026
Location: Budapest, Hungary

We are pleased to announce that MDPI will participate in the 2026 Annual Congress of the European Association for Cancer Research (EACR 2026), held in Budapest, Hungary, from 8 to 11 June 2026.

The 2026 Annual Congress of the European Association for Cancer Research (EACR 2026) is a four-day congress dedicated to basic, preclinical and translational cancer research across a wide range of topics. The conference will highlight the latest research and bring together the cancer research community to inspire innovation and build knowledge, connections and collaborations.

The following MDPI journals will be represented at the conference:

• Cancers;
• JPM;
• Current Oncology;
• Onco;
• JCM;
• Cells;
• Diseases;
• Epigenomes;
• CIMB;
• Biologics;
• Life;
• Gastrointestinal Disorders;
• Clinics and Practice;
• DNA;
• IJMS;
• Diagnostics.

If you are planning to attend the above conference, please feel free to start an online conversation with us. Our delegates look forward to meeting you in person at booth #101 and answering any questions that you may have. For more information about the conference, please visit the following website: https://2026.eacr.org/.

Journal of Clinical Medicine (JCM, ISSN: 2077-0383), an international, peer-reviewed, open access journal dedicated to clinical medicine, is published online semimonthly by MDPI. We are pleased to announce that JCM has successfully hosted its first Academic Publishing Workshop: A TCRG (Translational Cardiovascular Research Group) Research Masterclass on 13 March 2026 at University of Buckingham and Milton Keynes University Hospital NHS Foundation Trust. 

We would like to express our sincere gratitude to Professor Attila Kardos for his full support in this workshop. We are delighted to have introduced JCM to medical students, postdoctoral researchers, and other early-career researchers through this offline workshop and to have shared key information regarding open access publishing. 

Below is a brief summary of the workshop:

• Initially, the host gave an introduction to the TCRG, the research completed at this institute and how the medical students in the audience may be able to benefit from collaborating with TCRG;
• To introduce the presentation, we explained who MDPI is and where the UK office is located. We talked about JCM, going over the journal metrics, article processing time, where it is indexed and the societies we collaborate with. We demonstrated the scope of the journal and highlighted the sections relevant for the audience who work in cardiology research. We introduced the Editorial Board and showed the Editorial Board Members who are located at Milton Keynes University Hospital, as well as authors from the institution;
• We talked about how to write a scientific paper, including how to do a literature search, how to structure a paper and how each section should be written, with examples from JCM. We then described how a manuscript should be formatted, for MDPI journals and more generally. Next, we explained the importance of raw data and proper citation of previous works, as well as citation/data policies at MDPI. Finally, we spoke about how to choose a journal;
• We addressed the role AI plays in academic publishing, including considerations both for reviewers and authors. We explained the editorial process at MDPI, highlighting the many manuscript checks done after manuscript submission. We advised the audience on responding to reviewer comments, as well as how to deal with manuscript rejection. 

We would like to thank all participants for joining this workshop. We hope you have gained a better understanding of JCM through this event. You are welcome to follow our social media accounts to follow our upcoming activities, and we look forward to your continued participation and valuable contributions.

We hope to continue to establish in-depth and diversified collaborations with early career researchers to foster academic exchange among young scientists. We are recruiting Editorial Board Members. And, to enrich this Section’s academic content and advancing frontier research, we welcome Special Issue Proposals. 

In addition, we invite you to join our upcoming  online webinar, “Advancement in the Diagnosis of ANOCA/INOCA”, which will be held on 29 April 2026. To learn more about the webinar information, please visit: https://sciforum.net/event/JCM-22.

Dear colleagues,

As the Editor-in-Chief of the Journal of Clinical Medicine (JCM, ISSN: 2077-0383), I am pleased to announce the recipient of the 2025 Young Investigator Award. The award has been granted to Mr. Hidenori Takahashi, a physician in the Department of Respiratory Medicine, Tokyo Shinagawa Hospital, Tokyo 140-8522, Japan.

Dr. Takahashi was selected in recognition of his outstanding research contributions across interdisciplinary areas of clinical medicine, particularly his work on eosinophilic myocarditis and related immune-mediated conditions. As the awardee, he will receive an honorarium of CHF 2000 and an electronic certificate.

The award was evaluated based on the applicants’ track record of producing groundbreaking research and their significant contribution to the advancement of their research field. Given the high quality of the applications, the evaluation process and final decision were challenging. We would like to thank all the applicants for submitting such a wide and fascinating range of research topics.

On behalf of the assessment committee, I congratulate the winner on this accomplishment.

Dr. Kent Doi
Editor-in-Chief of JCM
On behalf of the JCM 2025 Young Investigator Award Evaluation Committee

The FACE AHEAD Summit 2026 aims to bring together industry leaders and surgeons to leverage shared experiences and success stories, fostering a collaborative environment for growth and innovation. This unique event offers a prime opportunity for the community to network, engage, and exchange knowledge with the next generation of craniomaxillofacial professionals.

The following open access journals will be represented:

• CMTR;
• Oral;
• JCM;
• IJOM;
• Anatomia;
• Surgeries;
• J. Aesthetic Med.;
• Clinics and Practice.

If you are attending this conference, feel free to start an online conversation with us. Our delegates look forward to meeting you in person at booth #25 at the conference and answering any questions that you may have. For more information about this event, please visit the following website: https://faceahead.org/about/.

Journal of Clinical Medicine (JCM, ISSN: 2077-0383) is an open access journal dedicated to presenting the latest research findings in the field of clinical medicine and promoting knowledge exchange among medical researchers globally. We are delighted to share with you a selection of 2025 publications contributed by our Editorial Board Members. We extend our gratitude to all Editorial Board Members for their support and significant contributions. These selected papers have received many citations and cover nine sections of JCM, including (but not limited to) endocrinology and metabolism, mental health, cardiology, and clinical neurology. We welcome you to explore the full texts of these papers via the links below.

Further information about our Editorial Board Members can be found via https://www.mdpi.com/journal/jcm/editors.

Abstract submissions are also open for our online conference, the 4th International Online Conference on Clinical Medicine, chaired by our Editors-in-Chief, until 7 August 2026. To learn more, visit https://www.mdpi.com/journal/jcm/events.

1. “Muscle in Endocrinology: From Skeletal Muscle Hormone Regulation to Myokine Secretion and Its Implications in Endocrine–Metabolic Diseases”
   by Pedro Iglesias
   J. Clin. Med. 2025, 14(13), 4490; https://doi.org/10.3390/jcm14134490
   Full text available online: https://www.mdpi.com/2077-0383/14/13/4490
2. “Physician and Medical Student Burnout, a Narrative Literature Review: Challenges, Strategies, and a Call to Action”
   by Santiago Cotobal Rodeles, Francisco Javier Martín Sánchez and Manuel Martínez-Sellés
   J. Clin. Med. 2025, 14(7), 2263; https://doi.org/10.3390/jcm14072263
   Full text available online: https://www.mdpi.com/2077-0383/14/7/2263
3. “The Triad of Risk: Linking MASLD, Cardiovascular Disease and Type 2 Diabetes; From Pathophysiology to Treatment”
   by Eleni Michalopoulou, John Thymis, Stamatios Lampsas, George Pavlidis, Konstantinos Katogiannis, Dimitrios Vlachomitros, Eleni Katsanaki, Gavriella Kostelli, Sotirios Pililis, Loukia Pliouta et al.
   J. Clin. Med. 2025, 14(2), 428; https://doi.org/10.3390/jcm14020428
   Full text available online: https://www.mdpi.com/2077-0383/14/2/428
4. “The Role of NLRP3 Inflammasome in Type 2 Diabetes Mellitus and Its Macrovascular Complications”
   by Konstantinos Karamitsos, Evangelos Oikonomou, Panagiotis Theofilis, Ignatios Ikonomidis, Eva Kassi, Vaia Lambadiari, Elias Gialafos, Aikaterini Tsatsaragkou, Vasiliki-Chara Mystakidi, Konstantinos Zisimos et al.
   J. Clin. Med. 2025, 14(13), 4606; https://doi.org/10.3390/jcm14134606
   Full text available online: https://www.mdpi.com/2077-0383/14/13/4606
5. “Septic Cardiomyopathy: Difficult Definition, Challenging Diagnosis, Unclear Treatment”
   by George E. Zakynthinos, Grigorios Giamouzis, Andrew Xanthopoulos, Evangelos Oikonomou, Konstantinos Kalogeras, Nikitas Karavidas, Ilias E. Dimeas, Ioannis Gialamas, Maria Ioanna Gounaridi, Gerasimos Siasos et al.
   J. Clin. Med. 2025, 14(3), 986; https://doi.org/10.3390/jcm14030986
   Full text available online: https://www.mdpi.com/2077-0383/14/3/986
6. “The Epidemiology of Syphilis Worldwide in the Last Decade”
   by Francois Rosset, Valentina Celoria, Sergio Delmonte, Luca Mastorino, Nadia Sciamarrelli, Sara Boskovic, Simone Ribero and Pietro Quaglino
   J. Clin. Med. 2025, 14(15), 5308; https://doi.org/10.3390/jcm14155308
   Full text available online: https://www.mdpi.com/2077-0383/14/15/5308
7. “Antiphospholipid Syndrome: A Comprehensive Clinical Review”
   by Vasileios Patriarcheas, Georgios Tsamos, Dimitra Vasdeki, Elias Kotteas, Anastasios Kollias, Dimitris Nikas, Georgia Kaiafa and Evangelos Dimakakos
   J. Clin. Med. 2025, 14(3), 733; https://doi.org/10.3390/jcm14030733
   Full text available online: https://www.mdpi.com/2077-0383/14/3/733
8. “Acromegaly and Cardiovascular Disease: Associated Cardiovascular Risk Factors, Cardiovascular Prognosis, and Therapeutic Impact”
   by Pedro Iglesias
   J. Clin. Med. 2025, 14(6), 1906; https://doi.org/10.3390/jcm14061906
   Full text available online: https://www.mdpi.com/2077-0383/14/6/1906
9. “Effect of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) on Left Ventricular Mechanics in Patients Without Overt Cardiac Disease: A Systematic Review and Meta-Analysis”
   by Andrea Sonaglioni, Federica Cerini, Valeria Fagiani, Gian Luigi Nicolosi, Maria Grazia Rumi, Michele Lombardo and Paola Muti
   J. Clin. Med. 2025, 14(8), 2690; https://doi.org/10.3390/jcm14082690
   Full text available online: https://www.mdpi.com/2077-0383/14/8/2690
10. “Serum Lipids, Inflammation, and the Risk of Atrial Fibrillation: Pathophysiological Links and Clinical Evidence”
    by Alfredo Mauriello, Adriana Correra, Anna Chiara Maratea, Alfredo Caturano, Biagio Liccardo, Marco Alfonso Perrone, Antonio Giordano, Gerardo Nigro, Antonello D’Andrea and Vincenzo Russo
    J. Clin. Med. 2025, 14(5), 1652; https://doi.org/10.3390/jcm14051652
    Full text available online: https://www.mdpi.com/2077-0383/14/5/1652
11. “Emerging Therapies in Inflammatory Bowel Disease: A Comprehensive Review”
    by John K. Appiah, Umar Hayat, Nikita Garg, Richeal Asante, Evans Donneyong, Muhammad U. Haider, Pranav Patel, Zubair Khan and Ali A. Siddiqui
    J. Clin. Med. 2025, 14(17), 6119; https://doi.org/10.3390/jcm14176119
    Full text available online: https://www.mdpi.com/2077-0383/14/17/6119
12. “Lipoprotein(a) as a Stroke Biomarker: Pathophysiological Pathways and Therapeutic Implications”
    by Evangelos Panagiotopoulos, Lina Palaiodimou, Aikaterini Theodorou, Georgia Papagiannopoulou, Eleni Bakola, Maria Chondrogianni, Klearchos Psychogios, Odysseas Kargiotis, Apostolos Safouris, Charalambos Vlachopoulos et al.
    J. Clin. Med. 2025, 14(9), 2990; https://doi.org/10.3390/jcm14092990
    Full text available online: https://www.mdpi.com/2077-0383/14/9/2990
13. “Frailty in Geriatrics: A Critical Review with Content Analysis of Instruments, Overlapping Constructs, and Challenges in Diagnosis and Prognostic Precision”
    by José Fierro-Marrero, Álvaro Reina-Varona, Alba Paris-Alemany and Roy La Touche
    J. Clin. Med. 2025, 14(6), 1808; https://doi.org/10.3390/jcm14061808
    Full text available online: https://www.mdpi.com/2077-0383/14/6/1808
14. “Diagnostic and Prognostic Value of Hematological Parameters in Necrotizing Enterocolitis: A Systematic Review”
    by Rozeta Sokou, Petros Mantzios, Alexia Eleftheria Palioura, Andreas G. Tsantes, Alexandra Lianou, Daniele Piovani, Konstantina A. Tsante, Katerina Lampropoulou, Nicoletta Iacovidou and Stefanos Bonovas
    J. Clin. Med. 2025, 14(7), 2530; https://doi.org/10.3390/jcm14072530
    Full text available online: https://www.mdpi.com/2077-0383/14/7/2530

MDPI is pleased to announce our participation in the 63rd ERA Congress, which will be held from 3 to 6 June 2026 in Glasgow, Scotland, UK.

The 63rd ERA Congress will revolve around the theme of “Open your mind”. The seven main tracks can be explored via the following link: https://www.era-online.org/events/glasgow-2026/scientific-programme/.

The following MDPI journals will be represented:

• Biomedicines;
• Journal of Clinical Medicine;
• Kidney and Dialysis;
• Cells;
• Anesthesia Research;
• Toxins;
• Diseases;
• Clinics and Practice;
• Diabetology;
• Transplantology;
• Medical Sciences;
• Journal of Molecular Pathology.

If you are attending 63rd ERA Congress, we invite you to visit us at our booth #D.250. Our representatives will be available to discuss publishing opportunities, the benefits of open access, and answer any questions that you may have.

For more information about the conference, please visit its official website at https://www.era-online.org/events/glasgow-2026/.

Our portfolio of journals available for publishing up-to-date research in immediate open access format has been further expanded. In the first quarter of 2026, nine new journals released their inaugural issues and three transferred journals released their first issue as part of MDPI, covering the subjects of clinical medicine, chemistry, computer science & mathematics, engineering, environment & ecology, and social sciences & psychology.

We extend our gratitude to the Editors-in-Chief, Associate Editors, and Editorial Board Members who will shape the future course of these brand-new journals. Each journal is dedicated to upholding strong editorial standards through a thorough peer review process, ensuring impactful open access scholarship.

Please feel free to browse and discover more about the new journals below.

We would like to thank everyone who has supported the development of open access publishing. If you would like to create a new journal, you are welcome to send an application here or contact the New Journal Committee (newjournal-committee@mdpi.com).

It is our pleasure to welcome you to this webinar, which will focus on recent advancements in the diagnostic evaluation of ANOCA (Angina with Non-Obstructive Coronary Arteries) and INOCA (Ischaemia with Non-Obstructive Coronary Arteries). We are privileged to convene a panel of leading specialists who will present the latest scientific developments in both invasive and non-invasive diagnostic methodologies, with the objective of delineating the diverse endotypes associated with ANOCA and INOCA.

Our program will extend beyond the investigation of coronary microvascular dysfunction, incorporating an analysis of coronary vasoreactivity and its influence on both the epicardial and microvascular compartments. We will examine the physiological mechanisms underpinning coronary microcirculation and the associated pathophysiological processes. Additionally, the session will feature patient-reported experiences regarding their diagnostic pathways, providing critical insight into the often complex and multifaceted nature of disease recognition.

Throughout the webinar, distinguished experts representing the principal cardiovascular imaging modalities will critically evaluate the advantages and limitations of PET-CT, Cardiac MRI perfusion, and advanced stress echocardiography. These modalities will be considered in their capacity as supplementary non-invasive diagnostic tools, in conjunction with the gold standard of invasive functional coronary assessment, thereby enhancing the precision and scope of ANOCA/INOCA diagnosis.

We trust that this webinar will offer an enriching educational experience, equipping attendees with a deeper understanding of the pathophysiology and diagnostic challenges faced by patients. By streamlining diagnostic testing, we aim to promote early diagnosis and appropriate management, improving outcomes for those affected by these complex conditions.

Thank you for joining us, and we look forward to a stimulating and informative discussion.

Date: 29 April 2026
Time: 3:00 p.m. CEST | 2:00 p.m. BST | 9:00 a.m. EDT.
Register in advance at the following link:
https://us02web.zoom.us/webinar/register/4717731495620/WN_6IqRg8JvS2GtSN24SZHKYw
Webinar ID: 884 9857 0139
Webinar Secretariat: journal.webinar@mdpi.com
Webinar announcement: https://sciforum.net/event/JCM-22

Register now for free!

Program:

After registering, you will receive a confirmation email containing information about how to join the webinar. Registrations with academic or institutional email addresses will be prioritized.

Unable to attend? Feel free to still register; we will inform you when the recording is available.

Webinar Chair and Keynote Speakers:

• Prof. Dr. Attila Kardos, ¹ Department of Cardiology, Translational Cardiovascular Research Group, Milton Keynes University Hospital NHS Foundation Trust, United Kingdom; ² Faculty of Medicine and Health Sciences, University of Buckingham, Buckingham, United Kingdom;
• Prof. Dr. Juan Carlos Kaski, St George’s, University of London, London, United Kingdom;
• Ms. Maria George, INOCA International, United Kingdom;
• Dr. Giovanni Luigi De Maria, Oxford University Hospital, Oxford, United Kingdom;
• Prof. Roxy Senior, Royal Brompton Hospital, London, United Kingdom; Imperial College London, London, United Kingdom;
• Prof. Dr. Chiara Bucciarelli-Ducci, Royal Brompton Hospital, London, United Kingdom;
• Prof. Dr. Alessia Gimelli, Gabriele Monasterio Foundation, Pisa, Italy.

Relevant Special Issue:
“Coronary Artery Disease: Recent Developments and Emerging Trends”
Guest Editors: Prof. Dr. Attila Kardos and Dr. Tarun Mittal
Deadline for manuscript submissions: 20 October 2026